Key facts
- It has raised $4.5M.
- Notable investors include Innovate UK, Northstar Ventures, Praetura Ventures, Change Makers, Durham University — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for LightOx
- ·The full record, as it builds
Funding rounds
No funding rounds for LightOx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LightOx
Developer of cancer therapeutics and technology designed to improve patients' function and long-term outcomes with oral cancer. The company is engaged in the creation of light-activated drug compounds and treatments that selectively and effectively eliminate tumor cells without causing significant disruption to non-cancerous tissue and surrounding healthy cells, enabling the medical community to treat cancer more efficiently.
- Sector
- Healthcare
- HQ
- Newcastle upon Tyne, United Kingdom
- Founded
- 2016
- Employees
- 16
- Website
- lightox.co.uk/
- Ownership
- Privately Held (backing)
LightOx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LightOx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LightOx in its N-PORT filings yet. We sweep new filings monthly.